A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Neuro Pace Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,500 shares of NPCE stock, worth $141,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,500
Holding current value
$141,120
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$5.9 - $11.93 $61,950 - $125,265
10,500 New
10,500 $117,000

Others Institutions Holding NPCE

About NeuroPace Inc


  • Ticker NPCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,846,900
  • Market Cap $334M
  • Description
  • NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...
More about NPCE
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.